Inhibiting angiogenesis by oral immunisation with poly(1-caprolactone)- poly(ethylene glycol)-poly(1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor

Author

JianLin Long ; Wei Liu ; Lin Li ; Pan Wang ; MaLing Gou ; Meijuan Huang ; Gang Guo ; Ke Men ; ZhiYong Qian ; Yuquan Wei

Author_Institution

Dept. of Thoracic Oncology, Sichuan Univ., Chengdu, China

Volume

6

Issue

4

fYear

2011

fDate

4/1/2011 12:00:00 AM

Firstpage

221

Lastpage

225

Abstract

Attempts to neutralise basic fibroblast growth factor (BFGF) have met some success in blocking neovascularisation. The authors describe an oral protein vaccine based on human BFGF encapsulated poly(ε-caprolactone)εpoly(ethylene glycol)εpoly(ε-caprolactone) (PCEC) nanoparticles. The human BFGF encapsulated PCEC nanoparticles (BFGF/PCEC) were monodisperse with the mean diameter of 142εnm and can slow-released BFGF in vitro. After mice were orally immunised with four dosages of BFGF/PCEC nanoparticles, BFGF-specific autoantibody titer in sera was 1600. Furthermore, alginate-encapsulated tumour cell assay implied that oral immunisation with BFGF/PCEC efficiently inhibited angiogenesis in vivo. Thus, oral immunisation with BFGF/PCEC nanoparticles may be a novel strategy to suppress angiogenesis, and this vaccine may have promising application in cancer immunotherapy.

Keywords

biochemistry; biomedical materials; cancer; cellular biophysics; disperse systems; molecular biophysics; nanomedicine; nanoparticles; patient treatment; polymers; proteins; alginate-encapsulated tumour cell assay; angiogenesis; blocking neovascularisation; cancer immunotherapy; oral immunisation; oral protein vaccine; poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanoparticle-encapsulated basic fibroblast growth;

fLanguage

English

Journal_Title

Micro & Nano Letters, IET

Publisher

iet

ISSN

1750-0443

Type

jour

DOI

10.1049/mnl.2011.0059

Filename

5771628